Business UpdateNov 12, 2026, 04:47 PM
Starling Oncology Updates Investor Presentation and Reports 3Q26 Results
AI Summary
Starling Oncology, Inc. (TOI) has filed an updated investor presentation to be used in investor meetings. The presentation supersedes a prior version and includes forward-looking statements and non-GAAP financial measures. The company also reported its 3Q26 results, showing total revenue of $170M, a 24% year-over-year increase, with specialty pharmacy revenue growing 44% YoY to $109M and a gross margin of 24%. Adjusted EBITDA for the quarter was $3.4M, marking the second consecutive quarter of positive results.
Key Highlights
- Starling Oncology (TOI) released an updated investor presentation on November 12, 2026.
- The presentation supersedes a previous version furnished as Exhibit 99.1 to the Original Report.
- The company is providing an updated investor presentation for use in investor meetings.
- The presentation includes forward-looking statements and non-GAAP financial measures like Adjusted EBITDA.
- Starling Oncology reported 3Q26 revenue of $170M, a 24% YoY increase.
- Specialty pharmacy revenue was $109M in 3Q26, up 44% YoY with a 24% gross margin.
- 3Q26 Adjusted EBITDA was $3.4M, positive for the second consecutive quarter.
Price Impact
More from TOI